12 September 2022 Scorpion Therapeutics, Volastra Therapeutics and ReCode Therapeutics Selected in Fierce Biotech’s 2022 Fierce 15 read more
29 June 2022 ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M read more
15 June 2022 Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients read more
22 March 2022 Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations read more
